Raushan Singh

About

I am the Founder and CEO of Light-Hope Diagnostics, Inc. I have a PhD in biochemistry (from North Dakota State University, Fargo) and over 20 years of research experience in nucleic acid and protein biochemistry. I worked as a Principal Scientist (Scientist III) at Co-Diagnostics, Inc. Prior to that I was an American Heart Association postdoctoral fellow at the University of Massachusetts Medical School and a postdoctoral research scientist at the University of Utah School of Medicine.

Light-Hope Diagnostics, Inc. is developing IVD products for early diagnosis of multiple forms of human cancer by detecting cancer-specific RNA in liquid biopsy. Our proprietary method for long-term stabilization of our IVD products at a higher ambient temperature, eliminates the requirement of cold chain management, and thereby makes them accessible worldwide at an affordable cost.

Employment

• Light-Hope Diagnostics, Inc Founder, President & CEO
  2024 - Present
• Co-Diagnostics, Inc Scientist III
  2023 - 2024
• The University of Utah Postdoctoral Fellow
  2018 - 2022
• University of Massachusetts Medical School Postdoctoral Fellow with Craig Peterson
  2014 - 2018

Education

• North Dakota State University PhD
  2008 - 2014

Projects & Funding

Projects & funding information is unavailable.

Publications (16)

• Loquacious-PD regulates the terminus-dependent molecular recognition of Dicer-2 toward double-stranded RNA
  Chemical Communication(RSC) 2021 DOI: 10.1039/D1CC03843E
  +Save
• Transient kinetic studies of the antiviral Drosophila Dicer-2 reveal roles of ATP in self–nonself discrimination
  eLife 2021 DOI: 10.7554/eLife.65810
  +Save
• Binding of dsRNA by D. melanogaster Dicer-2 is substrate-dependent and regulated by Loquacious-PD
  bioRxiv 2020 DOI: 10.1101/2020.11.19.390161
  +Save
• A real-time, transient kinetic study of Drosophila melanogaster Dicer-2 elucidates mechanism of termini-dependent cleavage of dsRNA
  bioRxiv 2020 DOI: 10.1101/2020.09.29.319475
  +Save
• Transient Kinetic Analysis of SWR1C-Catalyzed H2A.Z Deposition Unravels the Impact of Nucleosome Dynamics and the Asymmetry of Histone Exchange
  Cell Reports 2019 DOI: 10.1016/j.celrep.2019.03.035
  +Save
• Mechanism of N-Acylthiourea-mediated activation of human histone deacetylase 8 (HDAC8) at molecular and cellular levels.
  2015 DOI: 10.1074/jbc.m114.600627
  +Save
• Suppression of Mammary Carcinogenesis Through Early Exposure to Dietary Lipotropes Occurs Primarily In Utero.
  2015 DOI: 10.1080/01635581.2015.1087039
  +Save
• Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme.
  2014 DOI: 10.1021/bi500711x
  +Save
• Mmp-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer.
  2014 DOI: 10.1021/mp500108p
  +Save
• Kinetic and thermodynamic rationale for suberoylanilide hydroxamic acid being a preferential human histone deacetylase 8 inhibitor as compared to the structurally similar ligand, trichostatin a.
  2013 DOI: 10.1021/bi400740x
  +Save